Abstract
Both sodium–glucose cotransporter protein (SGLT)-2 inhibitors and glucagon-like peptide (GLP)-1 receptor agonists, when added to other treatments for
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have